BeiGene, Ltd. exceeded analysts' expectations in earnings, triggering analysts to revise their models. The biotech company underwent a rebranding and moved its global base to
Switzerland. Their earnings call reported
strong growth and showcased its strength in hematology at EHA 2025. BeiGene, under its new name BeOne Medicines, showcased new profits. They managed to
sell the royalties from Amgen's lung cancer drug for $950 million, making significant strides in B-Cell cancer research in collaboration with nference. UBS and CLSA reiterated their buy ratings for BeiGene, further solidifying the company's strong position. In the first quarter of 2025, BeiGene announced strong financial results. Their drug
Tevimbra received positive support from CHMP as a first-line treatment for
Nasopharyngeal Cancer. Achievements such as winning a US patent dispute over cancer drugs and being speculated to be included in the Hang Seng index further enhance their reputation. BeiGene's products excel in the medical field as evidenced by the FDA approval of Tevimbra for unresectable or metastatic esophageal squamous cell carcinoma. Amid this growth, BeiGene proposed a name change, rebranding as BeOne Medicines.
BeiGene, Ltd. News Analytics from Mon, 20 Dec 2021 08:00:00 GMT to Fri, 19 Dec 2025 06:06:41 GMT -
Rating 9
- Innovation 6
- Information 8
- Rumor 3
